52.67 -0.31 (-0.59%)
After hours: 4:26PM EDT
|Bid||0.00 x 1800|
|Ask||0.00 x 800|
|Day's Range||51.78 - 53.28|
|52 Week Range||30.30 - 57.55|
|Beta (3Y Monthly)||0.62|
|PE Ratio (TTM)||39.10|
|Earnings Date||Nov 8, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||60.33|
If you are currently a shareholder in Globus Medical Inc (NYSE:GMED), or considering investing in the stock, you need to examine how the business generates cash, and how it is Read More...
AUDUBON, Pa., Oct. 19, 2018 -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the third quarter ended.
Three of the nine analysts covering Varian Medical Systems (VAR) in October have given the stock “strong buy” ratings, three have given it “hold” ratings, and three have given it “sell” ratings.
Globus Medical, Inc. (GMED), a leading musculoskeletal solutions company, announced today participation in Educational Workshops at the Orthopedic Trauma Association Annual Meeting October 17th- 20th in Orlando Florida. During the resident workshops from October 17th- 19th, Globus Medical will support educational sessions entitled, Trimalleolar Ankle Fracture with Unstable Syndesmosis and External Fixation of a Comminuted Pilon Fracture, featuring the ANTHEM® Ankle Fracture System and ARBOR® External Fixation System. The ANTHEM® Ankle Fracture System is a comprehensive set of low profile, anatomically-contoured plates for treatment of a variety of ankle fractures.
Varian Medical Systems (VAR) is expected to report net income of $105.05 million in the fourth quarter of fiscal 2018 compared to $82.7 million in the fourth quarter of fiscal 2017, a rise of 27.02%. The company’s net income translates to a net income per share of $1.13 in the fourth quarter of fiscal 2018 compared to $0.89 in the fourth quarter of fiscal 2017. Varian Medical Systems generated free cash flow of $340.0 million in fiscal 2017.
Varian’s gross margins for fiscal 2018 and fiscal 2019 are expected to be 44.23% and 44.15%, respectively. In comparison, the fiscal 2018 gross margins of its peers Globus Medical (GMED), Stryker (SYK), and Zimmer Biomet Holdings (ZBH) are expected to be 77.01%, 66.27%, and 71.91%, respectively. Varian Medical Systems is expected to incur selling, general, and administrative expenses of $140.77 million in the fourth quarter of fiscal 2018 compared to $51.70 million in the fourth quarter of fiscal 2017, a rise of more than 100%.
NEW YORK, Oct. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Short interest is low for GMED with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding GMED is favorable, with net inflows of $8.54 billion.
Globus Medical, Inc. (GMED), a leading musculoskeletal solutions company, announced today that a recent clinical study evaluating static versus expandable lateral lumbar interbody fusion devices was awarded best paper at the Society for Minimally Invasive Spine Surgery (SMISS) Annual Forum held last month. The study, led by Dr. Richard Frisch, an orthopedic surgeon at Southeastern Spine Institute, compared clinical and radiographic outcomes of sixty-four patients who underwent minimally invasive lateral lumber interbody fusion (LLIF) for symptomatic degenerative disc disease. At one year postoperative follow up, patients treated with Globus Medical’s expandable technology experienced significantly greater segmental lordosis and a significantly lower subsidence rate than those in the static group, based on radiographic evidence. Both the expandable and static spacer groups reported similar improvements in back pain scores with no significant differences in clinical outcomes.
True market leader Netflix, producer of award-winning shows such as "The Crown," is showing bullish action in recent weeks.
Globus Medical, Inc. (GMED), a leading musculoskeletal solutions company, will feature its ExcelsiusGPS® revolutionary robotic guidance and navigation system along with its latest advancements in expandable interbody technology at the North American Spine Society (NASS) Annual Meeting being held September 26-29, 2018 in Los Angeles, CA. Globus Medical’s participation at NASS includes two in-booth presentations from surgeons currently using ExcelsiusGPS® that highlight the versatility of robotic guidance and navigation in both minimally invasive and complex deformity procedures. In addition to the presentations, meeting attendees have the opportunity to discuss advancements in robotic surgery and experience the company’s most recent product innovations.
Growth stock Globus Medical, an expert in minimally invasive spinal surgery technology, has shown a balanced pace of EPS and revenue growth since 2009.
This analysis is intended to introduce important early concepts to people who are starting to invest and want to begin learning about how to value company based on its currentRead More...
Globus Medical, Inc. (GMED), a leading musculoskeletal solutions company, today announced the acquisition of Nemaris Inc., a privately held company that markets and develops Surgimap®, a leading surgical planning software platform. “The acquisition of Surgimap® bolsters Globus Medical’s efforts to advance the future of computer-assisted surgery with the goal of improving patient outcomes,” said Chief Executive Officer Dave Demski. “Software-enhanced solutions are critical components of the future of computer-assisted surgery, and Surgimap® is the leading surgical planning software technology in the spine market today.
Globus Medical, Inc. (GMED), a leading musculoskeletal solutions company, will feature its ExcelsiusGPS® revolutionary robotic guidance and navigation system along with its latest advancements in expandable interbody technology at the Society for Minimally Invasive Spine Surgery (SMISS) Annual Forum being held September 6-8, 2018, in Las Vegas, Nevada. As part of the Forum’s scientific agenda, two clinical studies will be presented highlighting Globus Medical’s expandable lateral interbody spacer technology designed to restore disc height, increase lordosis, and reduce subsidence compared to traditional static spacers. “As leaders in the musculoskeletal device industry, we are committed to supporting research, education, and development of medical advancements through minimally invasive spine surgery,” said Andrew Iott, Senior Vice President, Global Product Development.
In June 2018, Globus Medical Inc (NYSE:GMED) released its earnings update. Generally, analysts seem fairly confident, with earnings expected to grow by 21.4% in the upcoming year against the pastRead More...
Stryker’s (SYK) share price has been on an uptrend for the past 52 weeks. From its level of $138.36 on August 23, 2017, it rose steadily to $168.9 on January 26, 2018. Amid the broader market turmoil, Stryker stock touched a 2018 low of $148.01 on February 8, after which it rose to its current level of $169 in August.
Stryker’s (SYK) product categories include orthopedics, medical-surgical, neurotechnology, and spine. Sales of orthopedics products, including implants for use in hip and knee joint replacements and trauma and extremity surgeries, increased from $1.14 billion in the second quarter of 2017 to $1.23 billion in the second quarter of 2018.
Stryker’s (SYK) products and services cater to areas that include orthopedic products, surgical products, neurotechnology products, and spine products. Stryker’s products include implants for use in hip and knee joint replacements, surgical equipment, surgical navigation systems, endoscopic and communications systems, emergency medical equipment, and intensive care disposable products. Its neurotechnology and spine products include neurosurgical, neurovascular, and spinal implant devices.
NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Arena ...
Short interest is low for GMED with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The $1.22 billion in inflows that ETFs holding GMED received over the last one-month is a decline from earlier in the period and among the weakest of the past year.